Summary
Primary: * To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: * To assess the safety and tolerability of oxaliplatin * To assess time to progression and overall survival.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Have Locally advanced/metastatic squamous or adenocarcinoma of the cervix * Prior therapy with cisplatin allowed * First-line treatment may have been surgery,radiotherapy or chemotherapy either as a single agent or multi-modality therapy * Must have measurable disease * Histologically Proven Carcinoma of the cervix * ECOG PS ≤2 * No other serious concomitant illness * Fully recovered from any prior therapy * Lab: ANC \>1500 mm³, Platelets \> 100000 mm³, Creatinine ≤ 1.5 x Normal value, Bilirubin ≤ 1.5 x Normal value, SGPT (ALT) ≤ 2.5 x Normal value Exclusion Criteria: * Known allergy to one of the study drugs * Peripheral neuropathy \> grade2 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.